Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer patients. Priced at Rs 12,495, the drug aims to improve access and affordability for patients with bone metastases from various cancers. This initiative supports patients in retaining mobility during their cancer treatment.

See Full Page